Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

Emerging research suggests that chronic inflammation, rather than neurotransmitter deficiencies alone, may be a major factor ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on GH Research (GHRS – Research Report). The associated price ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday. Ritu Baral has given her Buy ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

The existing treatment options for those diagnosed with Major Depressive Disorder (MDD) and Treatment-Resistant Depression ...

Ultrasound is already used for diagnosis and therapy. Recent studies have found it also to be a safe, effective, and rapid ...

Around 63% of these participants had been classed with having treatment-resistant depression. Half the participants received ...

The stakes are high for psilocybin clinical trials — there’s a pressing need for a more effective medical solution in the fight against depression, especially treatment-resistant depression.